ReviewBritish journal of cancer2013
Targeted anti-vascular therapies for ovarian cancer: current evidence.
Review in British journal of cancer, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 41 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
41 citing papers in PubMed, 4 syntheses or guidelines pooled it.
- Angiogenesis Inhibitors for the Treatment of Ovarian Cancer: An Updated Systematic Review and Meta-analysis of Randomized Controlled Trials.International journal of gynecological cancer : official journal of the International Gynecological Cancer Society · 2018Pooled it
- The association between CDH1 promoter methylation and patients with ovarian cancer: a systematic meta-analysis.Journal of ovarian research · 2016Pooled it
- Association between glutathione S-transferase M 1 null genotype and risk of ovarian cancer: a meta-analysis.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2013Pooled it
- Association between RASSF1A promoter methylation and ovarian cancer: a meta-analysis.PloS one · 2013Pooled it
- Immunotherapy May Improve Tumor Sensitivity to Palliative Chemotherapy in Platinum Resistant Ovarian Cancer.The oncologist · 2023Article
- ATR Inhibitors in Platinum-Resistant Ovarian Cancer.Cancers · 2022Review
- Article
- Review
- Review
- Integrative network analysis identifies potential targets and drugs for ovarian cancer.BMC medical genomics · 2020Article
- Precision medicine for ovarian clear cell carcinoma based on gene alterations.International journal of clinical oncology · 2020Review
- Cancer stem cells contribute to angiogenesis and lymphangiogenesis in serous adenocarcinoma of the ovary.Angiogenesis · 2019Article
- New 2-Oxoindolin Phosphonates as Novel Agents to Treat Cancer: A Green Synthesis and Molecular Modeling.Molecules (Basel, Switzerland) · 2018Article
- Isoprenaline/β2-AR activates Plexin-A1/VEGFR2 signals via VEGF secretion in gastric cancer cells to promote tumor angiogenesis.BMC cancer · 2017Article
- Article
- Histopathological markers of treatment response and recurrence risk in ovarian cancers and borderline tumors.Der Pathologe · 2017Review
- Synthesis and evaluation of 5-(arylthio)-9H-pyrimido[4,5-b]indole-2,4-diamines as receptor tyrosine kinase and thymidylate synthase inhibitors and as antitumor agents.Bioorganic & medicinal chemistry letters · 2017Article
- Body weight changes in patients undergoing chemotherapy for ovarian cancer influence progression-free and overall survival.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2017Article
- Secreted CLIC3 drives cancer progression through its glutathione-dependent oxidoreductase activity.Nature communications · 2017Article
- An overview of the role of platelets in angiogenesis, apoptosis and autophagy in chronic myeloid leukaemia.Cancer cell international · 2017Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Ovarian cancer presents at advanced stage in around 75% of women, and despite improvements in treatments such as chemotherapy, the 5-year survival from the disease in women diagnosed between 1996 and 1999 in England and Wales was only 36%. Over 80% of patients with advanced ovarian cancer will relapse and despite a good chance of remission from further chemotherapy, they will usually die from their disease. Sequential treatment strategies are employed to maximise quality and length of life but patients eventually become resistant to cytotoxic agents. The expansion in understanding of the molecular biology that characterises cancer cells has led to the rapid development of new agents to target important pathways but the heterogeneity of ovarian cancer biology means that there is no predominant defect. This review attempts to discuss progress to date in tackling a more general target applicable to ovary cancer-angiogenesis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.